Save on Belzutifan with Coupons, Discounts & Savings Programs

Belzutifan is available as a 40 mg oral tablet.

Belzutifan treats kidney cancer. It may also be used to treat some types of cancer and tumors in people with von Hippel-Landau syndrome.

Belzutifan works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells.

The recommended dosage of Belzutifan is 120 mg administered orally once daily with or without food.

Belzutifan is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Belzutifan:

• Decreased hemoglobin
• Fatigue
• Increased creatinine
• Headache
• Dizziness
• Increased glucose
• Nausea

Serious side effects are rare with Belzutifan.

• Anemia
• Inform patients that Belzutifan can cause severe anemia that may require blood transfusions and that red
  blood cell levels will be monitored routinely during treatment. Advise patients to contact their healthcare
  provider if the patient experiences any symptoms suggestive of anemia.
• Hypoxia
• Inform patients that Belzutifan can cause severe hypoxia that may require discontinuation, supplemental
  oxygen, or hospitalization; and that oxygen levels will be monitored routinely during treatment. Advise
  patients to contact their healthcare provider if the patient experiences any symptoms suggestive of
  hypoxia

The following medications may interact with Belzutifan:

• UGT2B17 or CYP2C19 Inhibitors: Monitor for signs and symptoms of anemia and hypoxia and reduce the dosage of Belzutifan as recommended

Various FDA-approved generic manufacturers

Exposure to Belzutifan during pregnancy can cause
embryo-fetal harm. You should have your pregnancy status verified prior to the initiation of Belzutifan. If you can become pregnant, you should use effective non-hormonal contraception during treatment with Belzutifan and for 1 week after the last dose, since Belzutifan can render some hormonal contraceptives ineffective. Male patients with female partners of reproductive potential shoud use effective contraception during treatment with Belzutifan and for 1 week after the last dose.

• Welireg